Company news

Halozyme Therapeutics, Inc. news in 2026

Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Halozyme Provides Update on German Preliminary Injunction Hearing

November 19, 2026

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

November 6, 2026

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

November 6, 2026

Halozyme reports third quarter 2026 results and raises full year 2026 financial guidance

November 5, 2026

Halozyme to Report Third Quarter 2026 Financial and Operating Results

October 22, 2026

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

October 7, 2026

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

October 6, 2026

Halozyme Announces Appointment of Jim Daly to its Board of Directors

September 30, 2026

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

September 17, 2026

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

September 16, 2026

Halozyme Appoints Dannielle Appelhans to its Board of Directors

August 18, 2026

Halozyme reports record second quarter 2026 results, beats estimates and raises full year 2026 financial guidance

August 6, 2026

Halozyme to Report Second Quarter 2026 Financial and Operating Results

July 23, 2026

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology

July 21, 2026

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

July 20, 2026

Halozyme Appoints David Ramsay as President Drug Delivery

June 30, 2026

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

June 15, 2026

Halozyme reports first quarter 2026 results and reiterates 2026 financial guidance

May 11, 2026

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

May 7, 2026

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

May 6, 2026

Halozyme to Report First Quarter 2026 Financial and Operating Results

April 30, 2026

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

April 30, 2026

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")

April 14, 2026

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

April 6, 2026

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

March 11, 2026

Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science

March 10, 2026

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

March 6, 2026

Russell Investments Expands Canadian ETF Lineup With Five New Offerings

February 18, 2026

Halozyme reports full year 2025 record revenue of $1.4 billion and reiterates strong 2026 Financial Guidance

February 17, 2026

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

February 10, 2026

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

January 28, 2026

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

January 20, 2026

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

January 7, 2026

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

January 4, 2026

Calls in 2026

Decks in 2026